Cite
HARVARD Citation
Harrington, K. et al. (n.d.). Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet oncology. 18 (8), pp. 1104-1115. [Online].